Radiopharmacokinetic modelling and radiation dose assessment of (223)Ra used for treatment of metastatic castration-resistant prostate cancer

PURPOSE: Ra-223 dichloride ((223)Ra, Xofigo®) is used for treatment of patients suffering from castration-resistant metastatic prostate cancer. The objective of this work was to apply the most recent biokinetic model for radium and its progeny to show their radiopharmacokinetic behaviour. Organ abso...

Descripción completa

Detalles Bibliográficos
Autores principales: Höllriegl, Vera, Petoussi-Henss, Nina, Hürkamp, Kerstin, Ocampo Ramos, Juan Camilo, Li, Wei Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172819/
https://www.ncbi.nlm.nih.gov/pubmed/34076794
http://dx.doi.org/10.1186/s40658-021-00388-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172819/
https://www.ncbi.nlm.nih.gov/pubmed/34076794
http://dx.doi.org/10.1186/s40658-021-00388-1

Ejemplares similares